Literature DB >> 15331916

S-nitroso human serum albumin improves oxygen metabolism during reperfusion after severe myocardial ischemia.

Martin Dworschak1, Maximilian Franz, Seth Hallström, Severin Semsroth, Harald Gasser, Markus Haisjackl, Bruno K Podesser, Tadeusz Malinski.   

Abstract

Nitric oxide (NO) supplementation may modify myocardial oxygen consumption and vascular function after ischemia. We investigated the effects of the NO donor, S-nitroso human serum albumin (S-NO-HSA), on cardiac oxygen metabolism during controlled reperfusion on normothermic cardiopulmonary bypass after severe myocardial ischemia. Pigs randomly received either S-NO-HSA or human serum albumin prior to and throughout global myocardial ischemia. Myocardial oxygen utilization is impaired at the onset of reperfusion, which is not amenable to S-NO-HSA. However, NO supplementation during ongoing supply dependency of oxygen consumption eventually leads to greater myocardial oxygen delivery and consumption. In conjunction with a better washout of lactate, this indicates an improved capillary perfusion in the S-NO-HSA group during reperfusion, which results in a better contractile function post bypass.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331916     DOI: 10.1159/000079139

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

Review 1.  Nitric oxide homeostasis as a target for drug additives to cardioplegia.

Authors:  B K Podesser; S Hallström
Journal:  Br J Pharmacol       Date:  2007-05-08       Impact factor: 8.739

2.  S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding.

Authors:  Yu Ishima; Takaaki Akaike; Ulrich Kragh-Hansen; Shuichi Hiroyama; Tomohiro Sawa; Ayaka Suenaga; Toru Maruyama; Toshiya Kai; Masaki Otagiri
Journal:  J Biol Chem       Date:  2008-10-20       Impact factor: 5.157

Review 3.  Evaluating Novel Targets of Ischemia Reperfusion Injury in Pig Models.

Authors:  Andrea Baehr; Nikolai Klymiuk; Christian Kupatt
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.